Press release
Irritable Bowel Syndrome Treatment Market to Grow at 8.5% CAGR, Hitting USD 7.4 Billion by 2032 | Persistence Market Research
The global irritable bowel syndrome (IBS) treatment market is projected to reach US$ 4.2 billion in 2025 and is expected to grow at a CAGR of 8.5% to attain a market size of US$ 7.4 billion by 2032. The rising prevalence of IBS, increasing awareness, advancements in medication, and growing adoption of targeted therapies are driving market expansion.IBS affects approximately 10% to 15% of the global population, with a higher incidence among women and the elderly. The IBS with constipation (IBS-C) segment is expected to dominate, holding 50.2% market share in 2025. Geographically, North America is the leading region, accounting for 38.2% of market share, due to advanced healthcare infrastructure and increasing awareness about IBS management.
Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/9938
Key Highlights from the Report
Rising prevalence of IBS, particularly in developed nations with stressful urban lifestyles.
Growing patient consultations due to increasing awareness of IBS symptoms and treatment options.
Increase in research and development activities to develop novel therapeutic approaches.
Higher adoption of combination therapies to manage multiple IBS symptoms effectively.
IBS-C is projected to capture 50.2% market share by 2025 due to advancements in constipation treatments.
Linaclotide is expected to dominate the product segment, accounting for 52% market share in 2025.
Market Segmentation
The IBS treatment market is categorized based on product type, treatment approach, and end-users:
By Product Type: The market includes Linaclotide, Rifaximin, Eluxadoline, Alosetron, Lubiprostone, and probiotics. Linaclotide remains the leading product due to its efficacy in managing IBS-C symptoms.
By Treatment Approach: IBS management involves pharmacological treatments, probiotics, dietary modifications, cognitive behavioral therapy, and gut microbiome modulation.
By End-Users: The primary end-users include hospitals, specialty clinics, and retail pharmacies, with retail pharmacies capturing 58% market share due to easy accessibility of over-the-counter IBS medications.
Regional Insights
North America: Market Leader
North America is projected to hold a 38.2% market share in 2025, driven by robust healthcare infrastructure, advanced diagnostic technologies, and higher adoption of targeted therapies. The prevalence of IBS in the region is 11%, with significant investments in gut microbiome research and digital health solutions improving IBS management.
Asia Pacific: Emerging Market
Asia Pacific is anticipated to account for 29.6% of the market share in 2025, growing at a CAGR of 9.8% through 2032. Factors such as increasing awareness, enhanced access to healthcare, and rising demand for innovative treatments are fueling growth. Japan and India are implementing digital health systems for personalized IBS treatment plans.
Market Drivers, Restraints, and Opportunities
Market Drivers
Growing Awareness About IBS Symptoms and Treatment: Rising education and awareness campaigns are encouraging early diagnosis and increasing patient consultations.
Advancements in Gut-Brain Axis Research: New therapies targeting gut microbiome modulation are enhancing treatment effectiveness.
Digital Health Innovations: Mobile apps for IBS symptom tracking and virtual consultations are expanding patient access to expert care.
Market Restraints
Social Stigma Surrounding IBS: Many patients hesitate to seek treatment due to embarrassment, leading to underdiagnosis and reduced market penetration.
Lack of Accurate Prevalence Data: The absence of comprehensive epidemiological studies affects investment in IBS-specific research and drug development.
Market Opportunities
Increasing R&D in Novel Therapies: Investments in microbiome-targeted drugs and combination therapies are shaping the next generation of IBS treatments.
Retail Pharmacies Enhancing Market Reach: The expansion of over-the-counter IBS medications and digital pharmacy solutions is improving treatment accessibility.
Reasons to Buy the Report
✔ Provides a detailed market forecast and CAGR analysis through 2032.
✔ Offers insights into key market drivers, restraints, and opportunities.
✔ Includes comprehensive segmentation analysis by product, treatment approach, and end-users.
✔ Examines regional growth trends, including emerging markets.
✔ Covers competitive landscape, key players, and recent industry developments.
Company Insights and Recent Developments
Key Players in the Market
AbbVie Inc.
Ironwood Pharmaceuticals, Inc.
Takeda Pharmaceuticals
Allergan plc
Bausch Health Companies Inc.
Astellas Pharma Inc.
Nestlé Health Science
Recent Industry Developments
July 2024: Eli Lilly acquired Morphic Holding, a company developing oral integrin therapies for IBS and other chronic diseases.
April 2024: Dr. Reddy's Laboratories launched DailyBloom IBS, India's first integrated care plan for IBS management.
The irritable bowel syndrome treatment market is evolving rapidly, with increasing research in gut microbiome, targeted therapies, and digital health solutions. As awareness and patient access improve, the industry is set for substantial growth in the coming years.
Contact Us:
Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com
About Persistence Market Research:
At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.
Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Irritable Bowel Syndrome Treatment Market to Grow at 8.5% CAGR, Hitting USD 7.4 Billion by 2032 | Persistence Market Research here
News-ID: 3932557 • Views: …
More Releases from Persistence Market Research

Plastic Liner Market to Reach US$ 6.67 Bn by 2030, Expanding at 4.7% CAGR - Pers …
➤ Overview of the Market
The global plastic liner market has gained steady traction across multiple industries due to its cost-effectiveness, versatility, and protective characteristics. Plastic liners are widely used in agriculture, mining, construction, waste management, and packaging industries, where they serve as an essential barrier to prevent leakage, contamination, and material loss. These liners are manufactured using materials such as polyethylene (PE), polypropylene (PP), and PVC, offering superior resistance to…

Returnable Plastic Crate Market to Reach US$ 2,665.1 Million by 2030 Fueled by S …
➤ Overview of the Market
The global returnable plastic crate market is gaining momentum as industries seek cost-effective and sustainable packaging solutions. These crates are widely used for transporting and storing perishable goods, beverages, pharmaceuticals, and industrial products due to their durability, stackability, and reusability. The shift from single-use packaging to eco-friendly alternatives has accelerated the adoption of returnable plastic crates across sectors. The market, valued at US$ 1,820.0 million in…

US Thermal Power Market Expected to Reach US$ 251.9 Mn by 2031 with 2.4% CAGR Gr …
➤Overview of the Market
The US thermal power market plays a crucial role in the nation's energy mix, serving as a stable and reliable source of electricity despite the rise of renewables. Thermal power plants in the US rely primarily on coal, natural gas, and oil to generate electricity, with natural gas emerging as the dominant fuel source due to its affordability, efficiency, and lower carbon footprint compared to coal. According…

Europe Medical Plastic Market to Reach US$ 17 Bn by 2032 Driven by Rising Health …
➤Overview of the Market
The Europe medical plastic market is undergoing robust growth, fueled by increasing demand for lightweight, durable, and cost-effective materials in the healthcare sector. Medical plastics are widely used in devices, surgical instruments, diagnostic tools, implants, and packaging due to their high biocompatibility, versatility, and resistance to sterilization methods. With healthcare systems across Europe investing heavily in modernization and patient safety, the adoption of medical-grade plastics has gained…
More Releases for IBS
Irritable Bowel Syndrome (IBS) Treatment Market Poised to Hit $7.68B by 2033 | S …
The Global Irritable Bowel Syndrome (IBS) Treatment Market reached US $3.61 billion in 2024 and is forecast to nearly double to US $7.68 billion by 2033, growing at a robust 8.8% CAGR from 2025 to 2033, according to DataM Intelligence's comprehensive report. IBS affects an estimated 5-10% of the global population, marking it one of the most prevalent gastrointestinal disorders with significant unmet medical needs.
👉 Download our latest market insights:…
Integrated Bridge Systems Market Report 2018: Segmentation by Platform (Commerci …
Global Integrated Bridge Systems market research report provides company profile for Northrop Grumman Sperry Marine (U.K.), Raytheon Anschütz (Germany), Rolls Royce (U.K.), L-3 Communications Mapps Inc. (Canada), FURUNO Electric Shokai Ltd. (Japan) and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR…
IBS' solution to power China’s first Cruise Line
Trivandrum, 16 January 2013: Henna, the largest cruise ship in mainland China will run on IBS’ inventory and pricing management solution, Cruise Partner, when it makes its maiden journey on January 26, 2013. China based HNA Tourism Cruise and Yacht Management Company unveiled this cruise ship on November 28, 2012. Henna has 739 rooms for 1,965 passengers, as well as a complete range of facilities for living and entertainment. HNA…
Vikash Sureka joins IBS as Chief Financial Officer
Trivandrum (India), 17 May 2012: IBS Software Services, the leading provider of new-generation IT solutions to the global aviation industry, has appointed Mr Vikash Sureka as its Chief Financial Officer. He will head the Finance, Legal, Company Affairs and Administration functions of IBS operations world-wide.
A Chartered Accountant, Vikash has over 19 years of experience mostly in senior executive roles managing business globally with proven proficiency in Investor Relations, P&L…
HaCon and IBS combine expertise in railway operation
Hanover (2010-07-06). Two Hanoverian companies now combine their expertise in questions of railway operations: With effect from 1 July 2010, the HaCon Ingenieurgesellschaft mbH, took over the engineering firm for railway operating systems (Ingenieurbüro für Bahnbetriebssysteme GmbH – IBS). This way HaCon expanded its services to include the areas operation simulation, vehicle and personnel planning and construction operations planning.
This also includes consulting services concerning railway systems issues, such as travel…
Raytheon Anschütz IBS for new Intership Bulkers
Raytheon Anschütz was recently awarded a contract to supply their Integrated Bridge System (IBS) to two new bulk carriers. The bulkers will be built at New Times Shipyard in Jingjiang, China. The delivery to the Cyprus based shipping company Intership Navigation Co. Ltd., a member of the German Hartmann Group, is scheduled for August and October 2011.
The new bulkers, each with a capacity of 176,000 dwt, will be equipped…